OverviewSuggest Edit

BioArctic is a research-based biopharmaceutical company mainly focused on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The Company is also focused on the development of treatment with a combination of a biodegradable medical device and a drug substance for complete spinal cord injury.

TypePublic
Founded2003
HQStockholm , SE
Websitebioarctic.se

Latest Updates

Employees (est.) (Dec 2021)49(+5%)
Share Price (Nov 2021)KR130(-1%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at BioArctic

Gunilla Osswald

Gunilla Osswald

Chief Executive Officer
Ivar Verner

Ivar Verner

Chairman
Jan Mattsson

Jan Mattsson

Vice President Finance, Chief Financial Officer
Wenche Rolfsen

Wenche Rolfsen

Chairman
Hans Ekelund

Hans Ekelund

Board Member
Gunilla Andersson

Gunilla Andersson

Senior Director HR
Show more

BioArctic Office Locations

BioArctic has an office in Stockholm
Stockholm , SE (HQ)
35 Warfvinges väg
Show all (1)

BioArctic Financials and Metrics

BioArctic Revenue

Market capitalization (10-Nov-2021)

11.4b

Closing stock price (10-Nov-2021)

130.0
BioArctic's current market capitalization is kr11.4 b.
Show all financial metrics

BioArctic Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

BioArctic Online and Social Media Presence

Embed Graph

BioArctic News and Updates

BioArctic presents Nomination Committee

STOCKHOLM, Nov. 1, 2021 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) Annual General Meeting on May 6, 2021, adopted an instruction regarding the appointment of the Nomination Committee. Pursuant to this instruction the company shall have a Nomination Committee...

BioArctic receives patent in Japan for new antibodies targeting Alzheimer's disease

STOCKHOLM, May 11, 2021 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Japanese Patent Office (JPO) has allowed the company's Japanese patent application 2017-083057 for novel antibodies that could be developed into a treatment for Alzheimer's...

Alligator Bioscience and BioArctic enter into research agreement in the neurodegenerative field

LUND, Sweden, May 4, 2021 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has entered into a joint research agreement with BioArctic AB, a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and...

BioArctic and Eisai presented latest data regarding lecanemab at AD/PD 2021

STOCKHOLM, March 15, 2021 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced data on the drug candidate lecanemab (BAN2401), which were presented by the company and its partner Eisai at the 15th International Conference on Alzheimer's and Parkinson's Diseases...

BioArctic receives European patent for new antibodies targeting Alzheimer's disease

STOCKHOLM, Jan. 27, 2021 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer's...

BioArctic winner of the Allbright Award 2020

STOCKHOLM, Oct. 15, 2020 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has been awarded the 2020 Allbright Award for its focused work with gender equality. The announcement was made on October 15 during Allbright's annual award ceremony in...
Show more

BioArctic Blogs

Invitation to presentation of BioArctic’s Interim Report for the second quarter of 2019 on July 11 at 9.30 a.m. CET

Stockholm, Sweden, July 2, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – June 2019 on Thursday, July 11, 2019 at 08:00 a.m. CET. BioArctic invites to an audiocast with teleconference (in English) for investors, analysts and med…

BioArctic strengthens its blood-brain barrier technology platform with world leading scientist recruitment

Stockholm, Sweden, May 23, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has recruited the internationally renowned scientist Dr. Per-Ola Freskgård to strengthen BioArctic’s development of its technology platform to facilitate passage of antibodies and other …

BioArctic receives MEUR 15 milestone payment from Eisai for start of BAN2401 confirmatory Phase 3 study in early Alzheimer’s Disease

Stockholm, Sweden, May 20, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company will receive a milestone payment of MEUR 15 from its partner Eisai for the achievement of the first patient being dosed in the global, single confirmatory Phase 3 study (Clarity AD) with…

BioArctic participates at Dementia Forum X

BioArctic’s CEO Gunilla Osswald speaking at the Dementia Forum X at the Royal Palace in Stockholm, participating in a global initiative to fight dementia.

BioArctic: Alzheimer’s Clinical Trials Consortium and Eisai announce BAN2401 to be evaluated in clinical study for prevention of Alzheimer’s disease

  Stockholm, Sweden, May 10, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informed today that the Alzheimer’s Clinical Trials Consortium (ACTC) and BioArctic’s partner Eisai have announced the selection of BAN2401 to be evaluated in an upcoming clinical study targeting secondary prevention …

BioArctic’s Board of Directors and management increase their shareholdings

Stockholm, Sweden, May 9, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that nine members of the company's Board and management today have called for redemption of share options in accordance with the option agreement concluded with the principal owners of BioArctic AB.
Show more

BioArctic Frequently Asked Questions

  • When was BioArctic founded?

    BioArctic was founded in 2003.

  • Who are BioArctic key executives?

    BioArctic's key executives are Gunilla Osswald, Ivar Verner and Jan Mattsson.

  • How many employees does BioArctic have?

    BioArctic has 49 employees.

  • Who are BioArctic competitors?

    Competitors of BioArctic include Iceni Diagnostics, Arotec Diagnostics and 3B Pharmaceuticals.

  • Where is BioArctic headquarters?

    BioArctic headquarters is located at 35 Warfvinges väg, Stockholm .

  • Where are BioArctic offices?

    BioArctic has an office in Stockholm.

  • How many offices does BioArctic have?

    BioArctic has 1 office.